The National Institute for Health and Clinical Excellence has now changed its guidance to the provision of these medications for people in the mild to moderate stages of the disease.
“This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically:
- donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and
- memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease”
Let us know what your experiences have been when requesting these medications, have you been freely offered them by your doctor and do you have any advise to pass onto others when it comes to medications. Use our contact page.
